Opinion|Videos|March 7, 2024
Dose Modifications and Tolerability Associated with mCRC Treatment Regimens
Managing dose adjustments and tolerability in metastatic colorectal cancer (mCRC) treatment regimens for optimal efficacy is underscored.
Advertisement
Episodes in this series
Advertisement
Related to this article
Andrea Cercek, MD, discusses the FDA approval of dostarlimab and its significance for dMMR locally advanced rectal cancer management.
The designation covers QTX3034 plus cetuximab with or without FOLFOX; phase 1 data showed a 25% confirmed ORR with the doublet in CRC and PDAC.
In TASKIN, the 12-month OS rate was 61.3% with vilamakitug vs 55.7% with placebo plus trifluridine/tipiracil.
The FDA has approved dostarlimab for MSI-H or dMMR locally advanced rectal cancer.
The top 5 OncLive TV videos of the week cover insights in multiple myeloma, HR+ breast cancer, CAR T-cell therapy, CLL, and oral SERDs.
Invikafusp alfa now holds fast track status across TMB-H solid tumors that progressed after prior therapy, including checkpoint inhibition.
The FDA has approved atezolizumab in combination with chemotherapy for some patients with stage 3 colon cancer following surgery.
Conditional approvals in Armenia cover botensilimab plus balstilimab indicated for patients with MSS mCRC without active liver metastases.
Advertisement
Advertisement
Trending on OncLive
1
Tolerability Remains a TROP2-Directed ADC Hurdle in EGFR-Mutated NSCLC
2
Pembrolizumab Plus Enfortumab Vedotin Earns EC Approval in Resectable MIBC
3
Experts Tackle Key Questions on CDK4/6 Inhibition Across HR+ Breast Cancer Settings
4
Dr Oberstein on the Rationale for Evaluating the PD-1/IL-15 Fusion Protein SAR445877 in MSS CRC
5